News | September 24, 2014

Study Compares Efficacy of Bioresorbable Stent to Best-in-Class Drug-Eluting Stents

Results of EVERBIO II trial reported at TCT 2014

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated satisfactory and comparable angiographic and clinical outcomes compared to the two drug-eluting stents (DES). Findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

Bioresorbable vascular scaffolds are thought to reduce long-term complications, such as neoatherosclerosis and very late stent thrombosis, by restoring more physiological vascular function. While current evidence demonstrates the feasibility of BVS implantation in simple patients and non-complex lesions, BVS is increasingly used in complex patients and lesions. The EVERBIO II trial is the first to compare the efficacy of BVS in all comers with new generation DES.

The single-center, parallel-group, assessor-blind, randomized controlled trial enrolled a total of 238 patients with either stable coronary artery disease or acute coronary syndrome undergoing percutaneous coronary intervention (PCI). Minimal exclusion criteria were used. Patients were randomly assigned to receive either BVS, everolimus-eluting stent (EES) or biolimus-eluting stents (BES). The primary endpoint was late lumen loss at 9 months measured by quantitative coronary angiography. Secondary endpoints were patient and device-oriented major adverse coronary events (MACE) at 12 months.

Eighty patients each were enrolled in the BES group and EES group, and 78 patients received BVS implantation. After nine months, in-stent late lumen loss was 0.25±0.36 in the EES/BES group and 0.28±0.39 in the BVS group (p=0.30). Device-oriented MACE occurred in 9 percent (n=15) in the EES/BES group and 12 percent (n=9) in the BVS group (p=0.6). Patient-oriented MACE occurred in 26 percent (n=41) in the EES/BES group and 27 percent (n=21) in the BVS group (p=0.83).

“In a patient population with minimal exclusion criteria, and using late lumen loss as an early and robust marker for restenosis, BVS demonstrated satisfactory angiographic and clinical outcomes compared to EES and BES,” said lead investigator Stéphane Cook, M.D., from the Hospital and University of Fribourg in Switzerland. “While in-segment late lumen loss was slightly but significantly higher in BVS compared to EES and BES, the EVERBIO II trial demonstrates that implantation of everolimus-eluting biodegradable scaffold is similar to new generation drug-eluting stents for the primary angiographic endpoint and secondary clinical endpoints.”

The EVERBIO II trial was funded by Fonds Scientifique Cardiovasculaire. Cook reported receiving speaker fee and honoraria from Abbot Vascular, Biosensors, Boston Scientific, Cordis and St. Jude Medical. Cook also receives support from the Swiss National Science Foundation.

For more information: www.crf.org, www.tctconference.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init